SG11201900895QA - Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy - Google Patents
Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopyInfo
- Publication number
- SG11201900895QA SG11201900895QA SG11201900895QA SG11201900895QA SG11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA
- Authority
- SG
- Singapore
- Prior art keywords
- self
- international
- protein
- assay
- michael
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 238000003556 assay Methods 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 238000004611 spectroscopical analysis Methods 0.000 title abstract 3
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 1
- 235000020061 kirsch Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Plasma & Fusion (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 February 2018 (22.02.2018) WIPO I PCT 11111111111101101111111111101101011 H 01100 1111101110# (10) International Publication Number WO 2018/035470 A9 (51) International Patent Classification: G01N 33/50 (2006.01) GO1N 33/68 (2006.01) (21) International Application Number: PCT/US2017/047630 (22) International Filing Date: 18 August 2017 (18.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/376,788 18 August 2016 (18.08.2016) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Rd., Tarrytown, New York 10591 (US). (72) Inventors: MARLOW, Michael; 11 Park Place, Apt. 409, New Rochelle, New York 10801 (US). SENNETT, Michael; 182 Powder House Blvd., Sommerville, Massa- chusetts 02144 (US). SCHNEIDER, Michael; c/o Regen- eron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd., Tarrytown, New York 10591 (US). = (74) Agent: KIRSCH, Gregory J.; Smith Gambrell & Russell LLP, 1230 Peachtree Street, N.E., Suite 3100, Promenade, Atlanta, GA 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (48) Date of publication of this corrected version: 05 July 2018 (05.07.2018) (15) Information about Correction: see Notice of 05 July 2018 (05.07.2018) O N O 00 O 0 (54) Title: ASSAY FOR DETERMINING POTENTIAL TO SELF-ASSOCIATION OF A PROTEIN USING CONCEN- TRATION-DEPENDENT SELF-INTERACTION NANOPARTICLE SPECTROSCOPY (57) : Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376788P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047630 WO2018035470A1 (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900895QA true SG11201900895QA (en) | 2019-02-27 |
Family
ID=59746357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900895QA SG11201900895QA (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11428695B2 (en) |
| EP (2) | EP3500856B1 (en) |
| JP (3) | JP6959327B2 (en) |
| KR (3) | KR102534506B1 (en) |
| CN (2) | CN115468919A (en) |
| AU (2) | AU2017313150B2 (en) |
| BR (1) | BR112019003175A2 (en) |
| CA (1) | CA3032361A1 (en) |
| DK (2) | DK3500856T3 (en) |
| EA (1) | EA201990316A1 (en) |
| ES (1) | ES2837093T3 (en) |
| FI (1) | FI3761035T3 (en) |
| HU (1) | HUE052805T2 (en) |
| IL (2) | IL264640B2 (en) |
| MX (1) | MX2019001930A (en) |
| PL (1) | PL3500856T3 (en) |
| SG (1) | SG11201900895QA (en) |
| WO (1) | WO2018035470A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6959327B2 (en) | 2016-08-18 | 2021-11-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Assay to determine the likelihood of protein self-association using concentration-dependent self-interacting nanoparticle spectroscopy |
| WO2019217927A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
| WO2023095154A1 (en) * | 2021-11-24 | 2023-06-01 | Sensoville Biotech Pvt Ltd | Method for determining changes in a protein's structure |
| WO2023141319A1 (en) * | 2022-01-24 | 2023-07-27 | Amgen Inc. | Methods for detecting antibody self-association |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US771997A (en) | 1903-11-21 | 1904-10-11 | Alfred Palm | Lathe attachment. |
| US4254102A (en) * | 1975-09-08 | 1981-03-03 | Plough, Inc. | Substantive PABA compositions |
| US4080264A (en) | 1976-03-01 | 1978-03-21 | Massachusetts Institute Of Technology | Immunoassay by light scattering spectroscopy |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7514938B2 (en) | 2004-05-11 | 2009-04-07 | Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno | Dielectric relaxation spectroscopy apparatus and methods of use |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| US20070291265A1 (en) | 2006-04-13 | 2007-12-20 | Mississippi State University | Optical apparatus for simultaneously measuring the scattering and concentration of signals of macromolecules in a flow cell |
| KR20090069330A (en) * | 2006-10-12 | 2009-06-30 | 와이어쓰 | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| WO2010059963A2 (en) | 2008-11-21 | 2010-05-27 | The Board Of Regents Of The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
| EP2993460B1 (en) * | 2013-05-30 | 2019-07-03 | Osaka Prefecture University Public Corporation | Target-substance detection apparatus and method |
| EP3043774B1 (en) * | 2013-09-11 | 2020-11-04 | Eagle Biologics, Inc. | Liquid protein formulations containing ionic liquids |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| CN104062287B (en) * | 2014-07-01 | 2017-08-08 | 福建工程学院 | A kind of method that chemiluminescence analysis based on nano gold catalysis detects ferritin |
| MA40861A (en) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES |
| WO2016115475A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| JP6959327B2 (en) | 2016-08-18 | 2021-11-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Assay to determine the likelihood of protein self-association using concentration-dependent self-interacting nanoparticle spectroscopy |
-
2017
- 2017-08-18 JP JP2019508809A patent/JP6959327B2/en active Active
- 2017-08-18 US US16/326,238 patent/US11428695B2/en active Active
- 2017-08-18 MX MX2019001930A patent/MX2019001930A/en unknown
- 2017-08-18 WO PCT/US2017/047630 patent/WO2018035470A1/en unknown
- 2017-08-18 SG SG11201900895QA patent/SG11201900895QA/en unknown
- 2017-08-18 IL IL264640A patent/IL264640B2/en unknown
- 2017-08-18 PL PL17761159T patent/PL3500856T3/en unknown
- 2017-08-18 DK DK17761159.7T patent/DK3500856T3/en active
- 2017-08-18 AU AU2017313150A patent/AU2017313150B2/en active Active
- 2017-08-18 KR KR1020227030436A patent/KR102534506B1/en active IP Right Grant
- 2017-08-18 CA CA3032361A patent/CA3032361A1/en active Pending
- 2017-08-18 KR KR1020237016537A patent/KR20230074614A/en not_active Application Discontinuation
- 2017-08-18 IL IL307435A patent/IL307435A/en unknown
- 2017-08-18 FI FIEP20191942.0T patent/FI3761035T3/en active
- 2017-08-18 KR KR1020197006376A patent/KR102441221B1/en active IP Right Grant
- 2017-08-18 ES ES17761159T patent/ES2837093T3/en active Active
- 2017-08-18 CN CN202211108451.8A patent/CN115468919A/en active Pending
- 2017-08-18 CN CN201780050825.6A patent/CN109661577B/en active Active
- 2017-08-18 DK DK20191942.0T patent/DK3761035T3/en active
- 2017-08-18 HU HUE17761159A patent/HUE052805T2/en unknown
- 2017-08-18 EP EP17761159.7A patent/EP3500856B1/en active Active
- 2017-08-18 EP EP20191942.0A patent/EP3761035B1/en active Active
- 2017-08-18 BR BR112019003175A patent/BR112019003175A2/en unknown
- 2017-08-18 EA EA201990316A patent/EA201990316A1/en unknown
-
2021
- 2021-10-07 JP JP2021165510A patent/JP7321227B2/en active Active
-
2022
- 2022-07-20 US US17/868,983 patent/US20220357335A1/en active Pending
-
2023
- 2023-07-25 JP JP2023120438A patent/JP2023139189A/en active Pending
- 2023-12-04 AU AU2023274236A patent/AU2023274236A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201900895QA (en) | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof |